All GLG News Analyses Filed Under: Oncology

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC

Gleevec shows promise as targeted melanoma treatment

July 27, 2009

Analysis of:A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT | meeting.ascopubs.org

Gleevec (Imatinib), a target specific cancer treatment drug against KIT oncogene mutations, shows early evidence of efficacy in treating melanomas with susceptible genetic mutations, further support for a personalized medicine, targeted therapy, approach to treating melanoma and cancers in general.

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC

PLX-4032, the new great hope for targeted therapy in melanoma

July 27, 2009

Analysis of:Plexxikon announces PLX4032 Phase I Data showing objective responses in metastatic melanoma patients | www.plexxikon.com

PLX-4032, a Plexxikon drug being co-developed with Roche, has shown remarkable results in a Phase I trial for melanoma and appears poised for rapid progression through Phase II and Phase III testing with perhaps accelerated FDA approval on the horizon.

Nexavar and Xeloda - Yet Another Breast Cancer Combination Shows Benefit

July 26, 2009

Analysis by: GLG Expert Contributor

Analysis of:Phase II trial of Nexavar in combo with chemotherapy shows free survival benefits in breast cancer patients | www.pharmabiz.com

 Bayer HealthCare AG and Onyx Pharmaceuticals announced that the combination of Nexavar and Xeloda provided a progression free survival benefit in patients with metastatic, HER2-negative breast cancer.

Peplin could be beneficial.

July 26, 2009

Analysis by: GLG Expert Contributor

Analysis of:Peplin Initiates its Final Phase 3 Clinical Trial for PEP005 Gel in AK | www.pipelinereview.com

New product that only requires 2 application days over an area.  May be useful.  Typical source for a product like this, coming from a plant extract.  Considering that 5-flourouracil has several variations, but all have predictable reactions that need minimally a few weeks to heal, it is worth looking at.  I think that it is a small error in not mentioning the healing process from the therapy.

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Another option in NSCLC...?!?

July 2, 2009

Analysis of:IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

The approval of Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.  

Pre - Clinical research begining to reach Indian Shores !!!

June 12, 2009

Analysis by: GLG Expert Contributor

Analysis of:Jubilant, Endo Enter Development Pact | www.contractpharma.com

The confidence shown by Endo by concluding this deal is a testament to the Indian out sourcing story!!! The underlining here is: Jubilant built a Biotech production & Research facility; to make optimal use of their facility and recover thier investments faster out of the box thinking was required. Endo bought the concept and here we have deal which is win - win for both.

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC

PARP Inhibitor shows very encouraging results in metastatic breast cancer

June 3, 2009

Analysis of:Novel BSI-201 Targeted Therapy Holds Promise for Patients with Metastatic Triple-negative Breast Cancer | www.asco.org

PARP inhibitors affect cancer cells by altering their ability to replicate DNA and grow. In theory and in animal models, they work syngergistically with more traditional chemotherapy agents, since PARP inhibition should make chemotherapy (or any drug which damages DNA) more effective. This study was presented at an ASCO plenary session and the reported results are exciting, both for breast cancer and other cancers where these drugs have just begun to be studied.

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC

Dr. Eggermont discusses his approach to adjuvant therapy for high risk melanoma

May 14, 2009

Analysis of:Biologic Basic for New Adjuvant Therapy Approaches | www.worldmelanoma2009.com

Dr. Alexander Eggermont, a leader of the major multicenter melanoma research group (in EORTC) in Europe, presented his current concepts on adjuvant therapy for malignant melanoma as part of a special session at the 7th World Congress on Melanoma in Vienna, Austria. Dr. Eggermont had signficant comments on peg-intron, autoimmunity, and melanoma primary ulceration.

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC

Another melanoma drug fails in a late stage trial

May 14, 2009

Analysis of:Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint | sev.prnewswire.com

Nexavar, already approved in other oncology indications, has failed in its second attempt to treat malignant melanoma. An earlier trial, coined "PRISM," also failed to show any superiority for Nexavar combination therapy to chemotherapy alone. This may be a final setback for Nexavar therapy for melanoma.

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Iressa: will it be a new therapeutic option or will it replace another existing option?

May 4, 2009

Analysis of:IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

The recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommending to grant a marketing authorisation for Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.

Previous Page : 12345678910Next21 to 30 of 900